During a live event, Neil M. Iyengar, MD, discusses how genomic risk scores and menopausal status guide complex adjuvant therapy choices in breast cancer.
Targeted Oncology Staff
Articles by Targeted Oncology Staff
In separate, live events, Sandip P. Patel, MD; David P. Carbone, MD, PHD; and their event participants considered treatment options for a patient with metastatic non–small cell lung cancer.
During a live event, Nataliya Mar, MD, discussed a non–clear cell renal cell carcinoma trial of cabozantinib/nivolumab and how it compares to other combinations.
During a live event, Kashif Ali, MD, discussed outcomes from the NAPOLI 3 trial in terms of efficacy, tolerability, and dose modification.
August 2025 marked a transformative month in oncology as the FDA accelerates approvals for innovative cancer therapies, enhancing treatment options for patients.
This week in oncology highlights breakthroughs in cancer diagnostics and therapies, offering new hope for patients with colorectal, brain, ovarian, and breast cancers.
During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPiCS-02 trial.
During a live event, Raajit K. Rampal, MD, PhD, discusses managing a patient with low-risk polycythemia vera.
During a live event, Taha Al-Juhaishi, MD, discussed his experience treating blastic plasmacytoid dendritic cell neoplasm and getting patients to allogeneic transplant.
During a live event, Michael R. Bishop, MD, discussed efficacy and safety outcomes from the AGAVE-201 trial.
Catch up with the latest in oncology news from this week with this edition of The Targeted Pulse.
During a live event, Steven I. Robinson, MBBS, discussed desmoid tumor statistics and management for symptomatic progression.
During a live event, Kashif Ali, MD, reviewed the efficacy and safety of the NAPOLI 1 trial in patients with pancreatic cancer.
During a live event, Tian Zhang, MD, MHS, discussed options and recent trial data for treating metastatic hormone-sensitive prostate cancer.
Discover the latest breakthroughs in oncology, including FDA approvals and innovative treatments reshaping cancer care for patients and clinicians alike.
During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced neutropenia in SCLC.
During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.
During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.
Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment landscapes.
During a live event, Tony Philip, MD, recommended tailored imaging intervals and avoiding surgery and radiation for desmoid tumors.
During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should receive second-line CAR T-cell therapy.
During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting in multiple myeloma.
During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in patients with advanced melanoma.
During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal patient selection for CLL.
During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic renal cell carcinoma.
During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.
In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key discussions on trial access gaps.
July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment options for various cancers.
During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy.
This week: FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and TNBC research aims for safer treatments.